| Literature DB >> 28670429 |
Maryam Khademi Bami1, Masoud Dehghan Tezerjani2, Fateme Montazeri2, Hamid Reza Ashrafzadeh Mehrjardi2, Saeed Ghasemi-Esmailabad2, Mohammad Hasan Sheikhha2, Seyed Mehdi Kalantar2.
Abstract
BACKGROUND: Signaling molecules such as cytokines regulate spermatogenesis during the maturation of germ cells and sperm apoptosis. Tumor necrosis factor alpha (TNFα) is one of the most-documented cytokines that is involved in spermatogenesis. We investigated the association of the TNFα -308 G/A single nucleotide polymorphism with sperm abnormalities in Iranian males.Entities:
Keywords: Cytokines; Infertility; Polymorphism; Restriction Fragment Length Polymorphism; Tumor Necrosis Factor Alpha
Year: 2017 PMID: 28670429 PMCID: PMC5347448 DOI: 10.22074/ijfs.2017.4830
Source DB: PubMed Journal: Int J Fertil Steril ISSN: 2008-0778
Fig.1The results of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis of TNFα -308 polymorphism. Lane M shows the molecular weight marker, Lanes 1, 3 and 4 show the AA genotype. Lanes 2 and 5 show the GA genotype. Lane 6 shows the GG genotype.
The sperm parameters in the case group
| Group | Sperm parameter | Mean ± SD |
|---|---|---|
| Azoospermia | Sperm count (106/mL) | 0 |
| Oligospermia | Sperm count (106/mL) | 6.6 ± 2.3 |
| Asthenoteratospermia | Motility (grades a+b)%/Morphology (% normal forms) | 10.7 ± 5.8/4.7 ± 2.8 |
| Teratospermia | Morphology (% normal forms) | 6.9 ± 3.4 |
The frequencies of alleles and genotypes of the -308 G/A SNP in the TNFα promoter in the azoospermic, teratospermic, Asthenoteratospermic and Oligospermic groups
| Genotype-allele/group | Normospermic (%) n=100 | Azoospermic (%) n=91 | P; OR (95% CI) | Oligospermic (%) n=26 | P; OR (95% CI) |
|---|---|---|---|---|---|
| AA | 13 (13%) | 25 (27.4%) | 0.018; 2.535 (1.2-5.3)* | 7 (26.9%) | 0.040; 2.97 (1.076-8.22)* |
| AG | 22 (22%) | 30 (32.9%) | 0.010; 1.74 (0.916-3.20)* | 9 (34.6%) | 0.206; 1.87 (0.736-4.787) |
| GG* | 65 (65%) | 36 (39.5%) | Ref. | 10 (38.5%) | Ref. |
| AA+AG | 35 (35%) | 55 (60%) | 0.001; 2.837 (1.57-5.107)* | 16 (61%) | 0.024; 2.971 (1.22-7.240)* |
| A | 48 (24%) | 80 (43.9%) | <0.001; 2.484 (1.604-3.845)* | 23 (44.2%) | 0.005; 2.51 (1.32-4.7)* |
| G** | 152 (76%) | 102 (56%) | Ref. | 29 (55.8%) | Ref. |
| AA | 13 (13%) | 9 (30%) | 0.049; 2.86 (1.083-7.599)* | 5 (15.2%) | 0.772; 1.195 (0.392-3.648) |
| AG | 22 (22%) | 13 (43.3%) | 0.033; 2.71 (1.143-6.428)* | 8 (24.2%) | 0.812; 1.135 (0.449-2.864) |
| GG* | 65 (65%) | 8 (26.7%) | Ref. | 20 (60.6%) | Ref. |
| AA+AG | 35 (35%) | 22 (73%) | <0.001, 5.107 (2.061-12.657) | 13 (39%) | 0.679; 1.207 (0.537-2.714) |
| A | 48 (24%) | 31 (51.7%) | <0.001; 3.385 (1.85-6.17)* | 18 (27.3%) | 0.623; 1.18 (0.632-2.23) |
| G** | 152 (76%) | 29 (48.3%) | Ref. | 48 (72.7%) | Ref. |
TNFα; Tumor necrosis factor alpha, SNP; Single nucleotide polymorphism, OR; Odds ratios, CI; Confidence interval, *; Significant P<0.05. Ancestral genotypes GG* and alleles G** were taken as reference.